Increased prevalence of human polyomavirus JC viruria in chronic inflammatory rheumatic diseases patients in treatment with anti-TNF α: A 18 month follow-up study

Donatella Maria Rodio, Elena Anzivino, Monica Mischitelli, Anna Bellizzi, Rossana Scrivo, Daniela Scribano, Gianlorenzo Conte, Carla Prezioso, Maria Trancassini, Guido Valesini, Anna Teresa Palamara, Valeria Pietropaolo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chronic inflammatory rheumatic diseases (CIRDs) are immune-mediated pathologies involving joints. To date, TNFa-blocking agents administration is the most promising therapy, although these treatments are associated with an increased Polyomavirus JC (JCPyV) reactivation, the etiological agent of the Progressive Multifocal Leukoencephalopathy (PML). The aim of this study was the recruitment and the analysis of a CIRDs cohort in order to investigate a possible correlation between JCPyV presence and the influence of anti-TNF-α agents on viral loads. Blood and urine samples were collected from 34 CIRDs subjects prior the first anti-TNF-α infusion (T0) and after 3 (T3), 6 (T6), 12 (T12), and 18 (T18) months. Results showed persistent JC viruria significantly higher than JC viremia throughout the 18 month follow-up study (p = 0.002). In JCPyV positive samples, the non-coding control region (NCCR) was analyzed. Results evidenced archetypal structures (type II-S) in all isolates with the exception of a sequence isolated from a plasma sample, that corresponds to the type II-R found in PML subjects. Finally, the viral protein 1 (VP1) genotyping was performed and results showed the prevalence of the European genotypes 1A, 1B, and 4. Since only few studies have been carried out to understand whether there is a PML risk in CIRDs population infected by JCPyV, this study contributes to enrich literature insight on JCPyV biology in this cluster. Further investigations are necessary in order to recognize the real impact of biologics on JCPyV life cycle and to identify possible and specific viral variants related to increased virulence in CIRDs patients.

Original languageEnglish
Article number672
JournalFrontiers in Microbiology
Volume7
Issue numberMAY
DOIs
Publication statusPublished - 2016

Fingerprint

JC Virus
Rheumatic Diseases
Progressive Multifocal Leukoencephalopathy
Therapeutics
Viremia
Viral Proteins
Life Cycle Stages
Biological Products
Viral Load
Virulence
Joints
Genotype
Urine
Pathology
Population

Keywords

  • Anti-TNF-α
  • Chronic inflammatory rheumatic diseases
  • Human polyomavirus JC
  • NCCR
  • VP1

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Increased prevalence of human polyomavirus JC viruria in chronic inflammatory rheumatic diseases patients in treatment with anti-TNF α : A 18 month follow-up study. / Rodio, Donatella Maria; Anzivino, Elena; Mischitelli, Monica; Bellizzi, Anna; Scrivo, Rossana; Scribano, Daniela; Conte, Gianlorenzo; Prezioso, Carla; Trancassini, Maria; Valesini, Guido; Palamara, Anna Teresa; Pietropaolo, Valeria.

In: Frontiers in Microbiology, Vol. 7, No. MAY, 672, 2016.

Research output: Contribution to journalArticle

Rodio, DM, Anzivino, E, Mischitelli, M, Bellizzi, A, Scrivo, R, Scribano, D, Conte, G, Prezioso, C, Trancassini, M, Valesini, G, Palamara, AT & Pietropaolo, V 2016, 'Increased prevalence of human polyomavirus JC viruria in chronic inflammatory rheumatic diseases patients in treatment with anti-TNF α: A 18 month follow-up study', Frontiers in Microbiology, vol. 7, no. MAY, 672. https://doi.org/10.3389/fmicb.2016.00672
Rodio, Donatella Maria ; Anzivino, Elena ; Mischitelli, Monica ; Bellizzi, Anna ; Scrivo, Rossana ; Scribano, Daniela ; Conte, Gianlorenzo ; Prezioso, Carla ; Trancassini, Maria ; Valesini, Guido ; Palamara, Anna Teresa ; Pietropaolo, Valeria. / Increased prevalence of human polyomavirus JC viruria in chronic inflammatory rheumatic diseases patients in treatment with anti-TNF α : A 18 month follow-up study. In: Frontiers in Microbiology. 2016 ; Vol. 7, No. MAY.
@article{f80a0c4389504f0faf2e1cdd3414457a,
title = "Increased prevalence of human polyomavirus JC viruria in chronic inflammatory rheumatic diseases patients in treatment with anti-TNF α: A 18 month follow-up study",
abstract = "Chronic inflammatory rheumatic diseases (CIRDs) are immune-mediated pathologies involving joints. To date, TNFa-blocking agents administration is the most promising therapy, although these treatments are associated with an increased Polyomavirus JC (JCPyV) reactivation, the etiological agent of the Progressive Multifocal Leukoencephalopathy (PML). The aim of this study was the recruitment and the analysis of a CIRDs cohort in order to investigate a possible correlation between JCPyV presence and the influence of anti-TNF-α agents on viral loads. Blood and urine samples were collected from 34 CIRDs subjects prior the first anti-TNF-α infusion (T0) and after 3 (T3), 6 (T6), 12 (T12), and 18 (T18) months. Results showed persistent JC viruria significantly higher than JC viremia throughout the 18 month follow-up study (p = 0.002). In JCPyV positive samples, the non-coding control region (NCCR) was analyzed. Results evidenced archetypal structures (type II-S) in all isolates with the exception of a sequence isolated from a plasma sample, that corresponds to the type II-R found in PML subjects. Finally, the viral protein 1 (VP1) genotyping was performed and results showed the prevalence of the European genotypes 1A, 1B, and 4. Since only few studies have been carried out to understand whether there is a PML risk in CIRDs population infected by JCPyV, this study contributes to enrich literature insight on JCPyV biology in this cluster. Further investigations are necessary in order to recognize the real impact of biologics on JCPyV life cycle and to identify possible and specific viral variants related to increased virulence in CIRDs patients.",
keywords = "Anti-TNF-α, Chronic inflammatory rheumatic diseases, Human polyomavirus JC, NCCR, VP1",
author = "Rodio, {Donatella Maria} and Elena Anzivino and Monica Mischitelli and Anna Bellizzi and Rossana Scrivo and Daniela Scribano and Gianlorenzo Conte and Carla Prezioso and Maria Trancassini and Guido Valesini and Palamara, {Anna Teresa} and Valeria Pietropaolo",
year = "2016",
doi = "10.3389/fmicb.2016.00672",
language = "English",
volume = "7",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - Increased prevalence of human polyomavirus JC viruria in chronic inflammatory rheumatic diseases patients in treatment with anti-TNF α

T2 - A 18 month follow-up study

AU - Rodio, Donatella Maria

AU - Anzivino, Elena

AU - Mischitelli, Monica

AU - Bellizzi, Anna

AU - Scrivo, Rossana

AU - Scribano, Daniela

AU - Conte, Gianlorenzo

AU - Prezioso, Carla

AU - Trancassini, Maria

AU - Valesini, Guido

AU - Palamara, Anna Teresa

AU - Pietropaolo, Valeria

PY - 2016

Y1 - 2016

N2 - Chronic inflammatory rheumatic diseases (CIRDs) are immune-mediated pathologies involving joints. To date, TNFa-blocking agents administration is the most promising therapy, although these treatments are associated with an increased Polyomavirus JC (JCPyV) reactivation, the etiological agent of the Progressive Multifocal Leukoencephalopathy (PML). The aim of this study was the recruitment and the analysis of a CIRDs cohort in order to investigate a possible correlation between JCPyV presence and the influence of anti-TNF-α agents on viral loads. Blood and urine samples were collected from 34 CIRDs subjects prior the first anti-TNF-α infusion (T0) and after 3 (T3), 6 (T6), 12 (T12), and 18 (T18) months. Results showed persistent JC viruria significantly higher than JC viremia throughout the 18 month follow-up study (p = 0.002). In JCPyV positive samples, the non-coding control region (NCCR) was analyzed. Results evidenced archetypal structures (type II-S) in all isolates with the exception of a sequence isolated from a plasma sample, that corresponds to the type II-R found in PML subjects. Finally, the viral protein 1 (VP1) genotyping was performed and results showed the prevalence of the European genotypes 1A, 1B, and 4. Since only few studies have been carried out to understand whether there is a PML risk in CIRDs population infected by JCPyV, this study contributes to enrich literature insight on JCPyV biology in this cluster. Further investigations are necessary in order to recognize the real impact of biologics on JCPyV life cycle and to identify possible and specific viral variants related to increased virulence in CIRDs patients.

AB - Chronic inflammatory rheumatic diseases (CIRDs) are immune-mediated pathologies involving joints. To date, TNFa-blocking agents administration is the most promising therapy, although these treatments are associated with an increased Polyomavirus JC (JCPyV) reactivation, the etiological agent of the Progressive Multifocal Leukoencephalopathy (PML). The aim of this study was the recruitment and the analysis of a CIRDs cohort in order to investigate a possible correlation between JCPyV presence and the influence of anti-TNF-α agents on viral loads. Blood and urine samples were collected from 34 CIRDs subjects prior the first anti-TNF-α infusion (T0) and after 3 (T3), 6 (T6), 12 (T12), and 18 (T18) months. Results showed persistent JC viruria significantly higher than JC viremia throughout the 18 month follow-up study (p = 0.002). In JCPyV positive samples, the non-coding control region (NCCR) was analyzed. Results evidenced archetypal structures (type II-S) in all isolates with the exception of a sequence isolated from a plasma sample, that corresponds to the type II-R found in PML subjects. Finally, the viral protein 1 (VP1) genotyping was performed and results showed the prevalence of the European genotypes 1A, 1B, and 4. Since only few studies have been carried out to understand whether there is a PML risk in CIRDs population infected by JCPyV, this study contributes to enrich literature insight on JCPyV biology in this cluster. Further investigations are necessary in order to recognize the real impact of biologics on JCPyV life cycle and to identify possible and specific viral variants related to increased virulence in CIRDs patients.

KW - Anti-TNF-α

KW - Chronic inflammatory rheumatic diseases

KW - Human polyomavirus JC

KW - NCCR

KW - VP1

UR - http://www.scopus.com/inward/record.url?scp=84973549904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973549904&partnerID=8YFLogxK

U2 - 10.3389/fmicb.2016.00672

DO - 10.3389/fmicb.2016.00672

M3 - Article

AN - SCOPUS:84973549904

VL - 7

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - MAY

M1 - 672

ER -